Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective PPARgamma modulators with improved pharmacological profiles.

Kun Liu1, Regina M Black, John J Acton

  • 1Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA.

Bioorganic & Medicinal Chemistry Letters
|May 3, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR.

Journal of medicinal chemistry·2026
Same author

Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors.

Journal of medicinal chemistry·2024
Same author

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.

Circulation·2023
Same author

Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).

Journal of hepatology·2023
Same author

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.

Kidney international·2023
Same author

Endotrophin neutralization through targeted antibody treatment protects from renal fibrosis in a podocyte ablation model.

Molecular metabolism·2023
Same journal

Solid-phase synthesis and antimicrobial activities of lipid-neomycin conjugates.

Bioorganic & medicinal chemistry letters·2026
Same journal

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026
Same journal

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design and N-terminal acylation of a lactam-cyclized 11-residue antimicrobial peptide for improved antibacterial potency.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design, synthesis, and biological evaluation of chalcone hybrids including benzoylpiperazin (phenylacetylpiperazin)-thiophene as anti- Alzheimer's agents.

Bioorganic & medicinal chemistry letters·2026
Same journal

New aminopiperidine-azoles as antifungal agents against Candida albicans with mechanistic insights into the cAMP-PKA pathway.

Bioorganic & medicinal chemistry letters·2026
See all related articles
This summary is machine-generated.

New selective PPARgamma modulators (SPPARgammaMs) show reduced adipogenesis and potent glucose lowering effects in preclinical models. These compounds may offer a safer therapeutic approach by avoiding common side effects associated with full agonists.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Endocrinology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) is a key regulator of glucose metabolism and adipogenesis.
  • Selective PPARγ modulators (SPPARγMs) are being investigated as potential therapeutics for metabolic diseases.
  • Full PPARγ agonists can cause undesirable side effects, such as increased adipose tissue and heart weight.

Purpose of the Study:

  • To identify and characterize novel, metabolically robust N-benzyl-indole selective PPARγ modulators.
  • To evaluate the in vitro and in vivo efficacy and safety profiles of these novel compounds.

Main Methods:

  • Synthesis of N-benzyl-indole derivatives with benzoyl or benzisoxazoyl moieties.
  • In vitro assays to assess partial agonism at PPARγ and effects on adipogenesis in human adipocytes.

Related Experiment Videos

  • In vivo studies in db/db mice for glucose lowering and in rats to assess effects on heart weight and brown adipose tissue.

    • Main Results:

    • Identification of selective PPARγ modulators with reduced adipogenesis in vitro.
    • Demonstration of potent glucose-lowering effects in diabetic db/db mice.
    • Attenuation of increased heart weight and brown adipose tissue in rats compared to full agonists.

    Conclusions:

    • The novel SPPARγMs are partial agonists with a promising therapeutic profile.
    • These compounds effectively lower glucose and mitigate adverse effects associated with full PPARγ activation.
    • Further investigation is warranted for their potential in treating metabolic disorders.